Clinical Trial Update: This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile. [Phase 1]

View source ↗

Summary

This is a first-in-human Phase 1 trial to characterize pharmacokinetics, determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), and ass…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Snippet

Sponsor: Nanjing RegeneCore Biotech Co., Ltd. | Conditions: Hematologic Malignancies | Phase 1 | Status: RECRUITING